Gene therapy delivers functional genetic material into a patient's cells to treat or cure disease. Using viral vectors like AAV and lentivirus, or non-viral delivery methods such as lipid nanoparticles, gene therapy can replace defective genes, silence harmful ones, or add entirely new genetic instructions. With over a dozen FDA-approved gene therapies including Zolgensma, Luxturna, Hemgenix, and Casgevy, and a rapidly expanding clinical pipeline targeting cancer, blood disorders, neurological diseases, and blindness, gene therapy represents one of the most transformative frontiers in modern medicine.
Adeno-associated virus vectors for delivering therapeutic genes, the most widely used delivery vehicle
Fat-based delivery particles used for in vivo CRISPR and mRNA therapeutics
Editing cells outside the body and returning them to the patient
Delivering gene editing tools directly inside the patient's body
Engineering immune cells with chimeric antigen receptors to fight cancer
Regulatory pathways and approved gene therapies from IND to BLA
In-depth analysis and expert-level coverage
Approved gene therapies now cost between $2.1 million and $4.25 million per patient. This guide breaks down the real prices, why they are so high, how insurance and payment models are evolving, and why the global access crisis remains the field's most urgent unsolved problem.
How insulin analogs evolved from 1920s pancreas extracts into engineered peptides that anchor modern diabetes therapy and biotech.
Leuprolide and other GnRH analogs are peptides that paradoxically shut down sex hormone production — the backbone of androgen deprivation therapy.
Octreotide is the cyclic 8-amino-acid analog of somatostatin that revolutionized treatment of acromegaly, carcinoid syndrome, and neuroendocrine tumors.
Teduglutide is the engineered GLP-2 peptide that lets short bowel syndrome patients absorb more nutrition and reduce reliance on IV feeding.
Teriparatide is the PTH 1-34 fragment that paradoxically builds bone instead of breaking it down — a landmark anabolic peptide for severe osteoporosis.
Gene therapy is moving beyond treating rare diseases to targeting aging itself, with AAV-delivered rejuvenation genes showing dramatic results in animal models and the first human experiments already underway.
What if a single injection could permanently lower your cholesterol — no more daily statins? Verve Therapeutics and CRISPR Therapeutics are making this a reality with gene editing for cardiovascular disease.
Casgevy (exagamglogene autotemcel) made history as the first CRISPR-based gene therapy to receive regulatory approval — here's how it works and what it means for the future of genetic medicine.
In February 2026, the FDA unveiled a radical new framework: approve gene editing therapies for rare diseases based on 'plausible biological mechanism' rather than years of clinical endpoints. This could transform access to genetic medicines for thousands of diseases.
The FDA's February 2026 'plausible mechanism' pathway could revolutionize how gene therapies reach patients — especially for ultra-rare diseases where traditional trials are impossible.
How lipid nanoparticles -- the same technology behind COVID-19 mRNA vaccines -- are becoming the delivery vehicle of choice for in vivo gene editing therapies.
10 million people worldwide live with Parkinson's. Current drugs manage symptoms but don't stop progression. Gene therapy approaches — from AADC enzyme replacement to GDNF neurotrophic support — are showing promise in clinical trials.
What if a gene therapy could be designed for just one patient? N-of-1 personalized gene therapies are making this a reality — and the FDA just created a new pathway to approve them.
Current CAR-T therapies cost $400K+, take weeks to manufacture, and require each patient's own cells. Gene-edited 'off-the-shelf' CAR-T could treat any patient instantly — if scientists can solve the persistence problem.
Beta-thalassemia patients need blood transfusions every 2-4 weeks for life. Gene therapy is changing that — with Casgevy and Zynteglo already approved, and next-gen approaches in development.
Gene editing is transforming cancer treatment — from CRISPR-enhanced CAR-T cells that achieved 82% remission in leukemia to in vivo approaches that reprogram immune cells directly inside the body. Here's the complete landscape.
70,000 people worldwide live with cystic fibrosis. Trikafta transformed treatment, but it's not a cure and doesn't work for everyone. Gene editing could change that — with prime editing achieving 58% correction of the F508del mutation in lung cells.
Two gene therapies for sickle cell disease were approved on the same day. One uses CRISPR. The other uses gene addition. Here's how Casgevy and Lyfgenia compare — and why one company is failing.
The eye is the ideal organ for gene editing — immune-privileged, accessible, and small. From Luxturna to in vivo CRISPR, here's how gene editing is restoring vision.
Duchenne muscular dystrophy affects 1 in 3,500 boys. Sarepta's Elevidys became the first gene therapy approved for DMD — but generated controversy over efficacy, safety, and its $3.2M price tag. Here's the complete picture.
The same lipid nanoparticle technology that delivered COVID vaccines to billions is now delivering CRISPR to edit genes inside the body. Here's how the pandemic accelerated gene editing by a decade.
Hemgenix costs $3.5 million — the world's most expensive drug. Roctavian was withdrawn from Europe. Here's the full story of gene therapy for hemophilia: the science, the promise, and the problems.
Zolgensma was the first gene therapy to treat a leading genetic cause of infant death — and at $2.1M, one of the most expensive drugs ever created. Here's how it works, its impact, and what's next.
Accessible introductions for newcomers
Vertex Pharmaceuticals is pushing to expand Casgevy, the first approved CRISPR gene therapy, to children ages 5-11 with sickle cell disease. Here is why treating younger patients could prevent a lifetime of organ damage — and the challenges that come with it.
Two groundbreaking gene therapies — Casgevy and Lyfgenia — are transforming treatment for sickle cell disease. Here is how they work, how they compare, and what challenges remain.
How Casgevy became the first CRISPR-based gene therapy to win FDA approval, offering a potential cure for sickle cell disease.
Victoria Gray volunteered to be the first person in the United States treated with CRISPR gene editing, and her story has become a beacon of hope for millions living with sickle cell disease.
Katalin Kariko spent decades in obscurity pursuing mRNA therapeutics despite repeated rejection and demotion, until her breakthrough enabled COVID-19 vaccines and earned her the 2023 Nobel Prize.
CAR-T therapy costs $373,000-$475,000 per infusion and achieves 30-60% complete remission depending on cancer type. Here's the full breakdown of costs, outcomes, and what patients should know.
300 million people worldwide live with a rare disease, and 80% are genetic. Gene therapy and gene editing are offering hope where none existed — but access remains the biggest challenge.
A complete, up-to-date list of every FDA-approved gene therapy and cell therapy — from Kymriah (2017) to the latest 2025 approvals. Includes pricing, indications, and approval dates.
Gene therapies cost $850,000 to $4.25 million per patient. Here's exactly what each therapy costs, who pays, how insurance works, and why some therapies are failing commercially despite curing diseases.
From preclinical research to FDA approval, a new therapy takes 10-15 years and costs $1-2 billion to develop. Here's what happens at each stage — and what it means if you're considering participating.
Gene editing and gene therapy are turning 'incurable' genetic diseases into treatable — and even curable — conditions. Here are 10 diseases closest to a permanent cure.
Some gene therapies last a lifetime. Others fade after a few years. Here's why durability varies, what the long-term data shows, and what it means for patients.
A beginner's guide to gene therapy — how it delivers genetic fixes into cells, the different approaches, and why it's transforming medicine.
Adeno-associated virus (AAV) vectors deliver therapeutic genes in most approved gene therapies — from Zolgensma to Hemgenix. Here's how they work, their limitations, and what comes next.
GLP-1 drugs like Ozempic cost $1,000/month and require lifelong injections. What if a single gene edit could achieve the same effect permanently? Scientists are working on it.
Gene editing and gene therapy sound similar but work in fundamentally different ways. One adds a new gene copy. The other fixes the existing DNA. Here's the difference — and why it matters for patients.
Watch an AAV vector carry a therapeutic gene into a cell, from receptor binding to protein production. Understand gene therapy delivery visually.
Beginner · 2 minWatch a lipid nanoparticle carry mRNA into a cell — the same technology behind COVID vaccines and Intellia's breakthrough CRISPR therapy, explained visually.
Intermediate · 3 minTwo paths to genetic medicine compared visually — editing cells in the lab vs delivering gene therapy directly into the body. Understand when each approach is used.
Beginner · 2 minAdeno-Associated Virus — a small, non-pathogenic virus commonly used to deliver therapeutic genes into cells. The most widely used vector in gene therapy clinical trials.
An FDA pathway that allows earlier approval of drugs for serious conditions based on a surrogate endpoint (like biomarker changes) rather than clinical outcomes. Requires confirmatory post-market studies.
Biologics License Application — the application submitted to the FDA for approval to market a biological product (including gene therapies). Equivalent to an NDA for traditional drugs.
An FDA designation for drugs that treat serious conditions where preliminary evidence shows substantial improvement over existing treatments. Provides intensive FDA guidance and may speed development and review.
The protein shell of a virus or viral vector. AAV capsid engineering is a major area of research, as different capsids determine which tissues the vector can reach (tropism) and how the immune system responds.
Chimeric Antigen Receptor T-cell therapy — an immunotherapy that engineers a patient's T cells to recognize and attack cancer cells. Uses lentiviral or CRISPR-based approaches to add a synthetic receptor gene to the T cells.
The first CRISPR-based gene therapy approved by the FDA (December 2023). Treats sickle cell disease and beta-thalassemia by editing the BCL11A gene to reactivate fetal hemoglobin.
Data Safety Monitoring Board — an independent committee that reviews ongoing clinical trial data to ensure patient safety. Can recommend stopping a trial early for safety concerns or overwhelming efficacy.
A delivery technique that uses brief electrical pulses to create temporary pores in cell membranes, allowing gene editing components (like RNPs) to enter. Widely used in ex vivo therapies.
An AAV-based gene therapy for Duchenne muscular dystrophy that delivers a shortened version of the dystrophin gene (micro-dystrophin). Received accelerated approval from the FDA to treat ambulatory DMD patients.
Editing performed outside the body. Cells are removed from the patient, edited in the lab, and then infused back. Used by Casgevy for sickle cell disease treatment.
A medical approach that treats disease by adding, replacing, or modifying genetic material inside a patient's cells. Can use viral vectors (AAV, lentivirus) or non-viral delivery methods.
An AAV5-based gene therapy for hemophilia B approved by the FDA in 2022. Delivers a functional copy of the Factor IX gene to the liver, significantly reducing or eliminating the need for clotting factor infusions.
Editing performed directly inside the patient's body, typically by injecting the editing machinery (often in lipid nanoparticles) into the bloodstream. Intellia and Verve use this approach.
Investigational New Drug application — a request submitted to the FDA before a new drug or therapy can be tested in human clinical trials. Includes preclinical safety data, manufacturing information, and the proposed trial design.
| Therapy | Company | Disease | Phase | Status |
|---|---|---|---|---|
| Lyfgenia (lovotibeglogene autotemcel) | bluebird bio | Sickle cell disease | Approved | Approved |
| Zolgensma (onasemnogene abeparvovec) | Novartis Gene Therapies | Spinal muscular atrophy (SMA) Type 1 | Approved | Approved |
| Luxturna (voretigene neparvovec) | Spark Therapeutics / Roche | RPE65 mutation-associated inherited retinal dystrophy | Approved | Approved |
| Strimvelis | GSK / Orchard Therapeutics | Adenosine deaminase severe combined immunodeficiency (ADA-SCID) | Approved | Approved |
| Zynteglo (betibeglogene autotemcel) | bluebird bio | Transfusion-dependent beta-thalassemia | Approved | Approved |
| Hemgenix (etranacogene dezaparvovec) | CSL Behring / uniQure | Hemophilia B (Factor IX deficiency) | Approved | Approved |
| Elevidys (delandistrogene moxeparvovec) | Sarepta Therapeutics | Duchenne muscular dystrophy (DMD) | Approved | Approved |
| Roctavian (valoctocogene roxaparvovec) | BioMarin Pharmaceutical | Hemophilia A (Factor VIII deficiency) | Approved | Approved |
| Skysona (elivaldogene autotemcel) | bluebird bio | Cerebral adrenoleukodystrophy (CALD) | Approved | Approved |
| Lenmeldy (atidarsagene autotemcel) | Orchard Therapeutics | Metachromatic leukodystrophy (MLD) | Approved | Approved |